Condor Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-8,331
| Closed | -$427K | – | 226 |
|
|
2022
Q4 | $427K | Buy |
8,331
+298
| +4% | +$14.3K | 0.05% | 160 |
|
|
2022
Q3 | $352K | Sell |
8,033
-1,128
| -12% | -$54.8K | 0.05% | 165 |
|
|
2022
Q2 | $480K | Buy |
9,161
+66
| +0.7% | +$3.36K | 0.06% | 153 |
|
|
2022
Q1 | $471K | Buy |
9,095
+2,817
| +45% | +$146K | 0.05% | 156 |
|
|
2021
Q4 | $371K | Sell |
6,278
-88,613
| -93% | -$4.39M | 0.04% | 163 |
|
|
2021
Q3 | $4.08M | Buy |
94,891
+796
| +0.8% | +$35.3K | 0.43% | 58 |
|
|
2021
Q2 | $3.69M | Buy |
94,095
+125
| +0.1% | +$4.86K | 0.41% | 61 |
|
|
2021
Q1 | $3.4M | Buy |
93,970
+148
| +0.2% | +$5.25K | 0.4% | 62 |
|
|
2020
Q4 | $3.45M | Sell |
93,822
-5,016
| -5% | -$184K | 0.44% | 59 |
|
|
2020
Q3 | $3.44M | Sell |
98,838
-1,412
| -1% | -$49.5K | 0.5% | 54 |
|
|
2020
Q2 | $3.11M | Buy |
100,250
+2,866
| +3% | +$97.4K | 0.48% | 57 |
|
|
2020
Q1 | $3.02M | Sell |
97,384
-569
| -0.6% | -$19.4K | 0.56% | 49 |
|
|
2019
Q4 | $3.64M | Sell |
97,953
-673
| -0.7% | -$24K | 0.53% | 53 |
|
|
2019
Q3 | $3.36M | Sell |
98,626
-679
| -0.7% | -$24.7K | 0.52% | 53 |
|
|
2019
Q2 | $4.08M | Buy |
99,305
+10
| +0% | +$397 | 0.63% | 45 |
|
|
2019
Q1 | $4M | Buy |
99,295
+387
| +0.4% | +$15.5K | 0.65% | 43 |
|
|
2018
Q4 | $4.1M | Buy |
98,908
+7
| +0% | +$291 | 0.75% | 35 |
|
|
2018
Q3 | $4.13M | Buy |
98,901
+2
| +0% | +$77 | 0.75% | 29 |
|
|
2018
Q2 | $3.4M | Sell |
98,899
-673
| -0.7% | -$23K | 0.65% | 41 |
|
|
2018
Q1 | $3.35M | Sell |
99,572
-902
| -0.9% | -$31K | 0.73% | 36 |
|
|
2017
Q4 | $3.45M | Buy |
100,474
+513
| +0.5% | +$17.5K | 0.7% | 37 |
|
|
2017
Q3 | $3.39M | Buy |
99,961
+94
| +0.1% | +$3.02K | 0.68% | 34 |
|
|
2017
Q2 | $3.18M | Buy |
99,867
+3
| +0% | +$95 | 0.67% | 34 |
|
|
2017
Q1 | $3.24M | Sell |
99,864
-156
| -0.2% | -$4.92K | 0.7% | 32 |
|
|
2016
Q4 | $3.08M | Buy |
100,020
+371
| +0.4% | +$11.3K | 0.69% | 30 |
|
|
2016
Q3 | $3.2M | Hold |
99,649
| – | – | 0.75% | 29 |
|
|
2016
Q2 | $3.33M | Sell |
99,649
-650
| -0.6% | -$20.7K | 0.8% | 28 |
|
|
2016
Q1 | $2.82M | Buy |
100,299
+180
| +0.2% | +$5.14K | 0.68% | 34 |
|
|
2015
Q4 | $3.07M | Sell |
100,119
-1,273
| -1% | -$40K | 0.75% | 31 |
|
|
2015
Q3 | $3.02M | Sell |
101,392
-8,264
| -8% | -$265K | 0.79% | 26 |
|
|
2015
Q2 | $3.49M | Buy |
109,656
+276
| +0.3% | +$8.99K | 0.84% | 28 |
|
|
2015
Q1 | $3.61M | Buy |
+109,380
| New | +$3.48M | 0.86% | 27 |
|
Other funds holding PFE
Condor Capital Management's PFE Position: Q1 2023 in Review
Condor Capital Management sold out of Pfizer (PFE) in Q1 2023, closing a stake of 8,331 shares — an estimated $427K sold.
Condor Capital Management first reported a position in PFE in Q1 2015 and held it in 32 quarters. The position peaked at $4.13M in Q3 2018. 3,102 funds tracked by Wall St. Rank hold PFE as of Q1 2023.
- Condor Capital Management reported no remaining Pfizer position as of Q1 2023 after selling out during the quarter.
- Condor Capital Management sold 8,331 Pfizer shares in Q1 2023, an estimated $427K.
- Condor Capital Management first reported a position in Pfizer in Q1 2015 and held it in 32 quarters.
- Condor Capital Management's Pfizer position peaked at $4.13M in Q3 2018.
- 3,102 funds tracked by Wall St. Rank held Pfizer as of Q1 2023.
Based on Condor Capital Management's 13F filing for Q1 2023, filed 10 May 2023.